EGFR and neoplasm: Activating mutation in the KRAS gene, which is downstream of epidermal growth factor receptor (EGFR or ERBB1), is one of the most frequent mutations found in iCCA [100, 101]. KRAS gene mutations have been correlated with higher tumor stages (stage I, 8%; stage II, 15%; stage III, 31%; stage IV, 46%) [102].